Hester Bios Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 30 Jul 2026

Company page: Hester Bios share price, financials & guidance record

Hester Biosciences reported a strong Q1 FY27 on a standalone basis, with revenue growing 14% and PAT surging 88%, driven by improved gross margins (69% to 78%) and a 95% EBITDA growth. The Poultry Healthcare Division was a key performer, growing 48%. However, consolidated revenue declined 8% due to challenges in Nepal and Africa, and the Animal Healthcare Division faced delays in government programs. The company also benefited from a significant debt reduction and interest waiver for Hester Africa.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 15.9%, net profit up 87.5% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	74	63	77	63	65 −12%	70 +11%	94 +22%	73 +16%
Expenses	59	54	63	51	53	54	62	48
EBITDA	15	9	14	12	12 −20%	17 +89%	31 +121%	24 +100%
Margin	20%	14%	18%	20%	18%	24%	34%	34%
Other income	1	1	1	1	1	1	11	2
Interest	1	2	1	1	1	1	4	1
Depreciation	2	2	2	2	2	2	4	5
Profit before tax	12	6	11	10	10 −17%	15 +150%	35 +218%	20 +100%
Tax rate	25%	32%	16%	24%	27%	27%	24%	26%
Net profit	9	4	10	8	7 −22%	11 +175%	26 +160%	15 +88%
EPS	10.98	5.22	11.33	9.22	8.48	12.54	31.01	17.29

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls